Biomea Fusion has launched a Phase II trial of icovamenib in type 1 diabetes, advancing development of its experimental first-in-class therapy. The study follow

Biomea Fusion has launched a Phase II trial of icovamenib in type 1 diabetes, advancing development of its experimental first-in-class therapy. The study follows earlier Phase II data and reflects the ongoing need for alternatives to lifelong disease management.